Table 1 Demographics and baseline clinical characteristics of the study participants

Unique eyes after exclusion applied

1,295

149

1,444

Gender

 Female

527 (44.97)

59 (45.38)

586 (45.01)

1.00^†

Age at first nAMD diagnosed (yrs)

71.95 ± 8.27

71.93 ± 8.31

71.95 ± 8.27

0.94^‡

BCVA at baseline (logMAR)

0.70 ± 0.49

0.76 ± 0.51

0.71 ± 0.49

0.31^‡

BCVA after loading phase (logMAR)

0.54 ± 0.48

0.58 ± 0.47

0.55 ± 0.48

0.09^‡

Axial length (mm)^a

23.54 ± 0.90

23.62 ± 1.03

23.54 ± 0.91

Oculus

 Oculus dexter

647 (49.96)

76 (51.01)

723 (50.07)

0.88^†

nAMD subtype

0.26^†

 Type 1 or 2 CNV

969 (74.83)

115 (77.18)

1,084(75.07)

 PCV

208 (16.06)

17 (11.41)

225 (15.58)

 RAP (Type 3 CNV)

118 (9.11)

17 (11.41)

135 (9.35)

Anti-VEGF used for loading phase

0.55^†

 Ranibizumab

585 (45.17)

74 (49.66)

659 (45.64)

 Aflibercept

576 (44.48)

62 (41.61)

638 (44.18)

 Bevacizumab

134 (10.35)

13 (8.72)

147 (10.18)

Duration until the first recurrence (months)

7.87 ± 14.38

11.04 ± 23.28

8.20 ± 15.56

0.93^‡

OCT system

0.84^†

 Cirrus

798 (61.62)

90 (60.40)

888 (61.50)

 Spectralis

497 (38.38)

59 (39.60)

556 (38.50)